TABLE 1

Trial descriptions and meta-analysis results

StudyTiming and primary outcomeTotal patientsAverage ageMalesComorbiditiesSymptom free by day 14Hospitalised
DrugControlDrugControl
CONTAIN (placebo)≤6 days of symptoms
Resolution of cough, dyspnoea, and fever day 7
2033746.3%20.2% overall
5.9% HTN
2.5% diabetes
0.5% CAD
57/10544/986/1053/98
Covis Pharma (placebo)≤72 h of test
Time to symptom free
4004344.8%22% HTN
7.5% diabetes
81/19776/2033/1977/203
STOIC (open label)≤7 days of symptoms
COVID-19 urgent visits
1394542.4%Median of 1
8.4% CAD
5% diabetes
63/7048/692/7011/69
PRINCIPLE (open label)≤14 days of symptoms
COVID-19 related hospitalisation or death
1719 (concurrent)6448.5%80% (median of 1)
43–46% HTN
20–23% diabetes
15–17% CAD
251/781173/79472/78798/799
AnalysisPooled risk ratioProbability any benefitProbability NNT ≤50Probability NNT ≤20
RandomFixedRandomFixedRandomFixedRandomFixed
Symptom free day 14 (I2 30%)1.29 (1.14–1.47)1.31 (1.18–1.45)100%100%99.8%100%93.1%98.2%
Placebo-controlled (I2 0%)1.15 (0.95–1.38)1.15 (0.95–1.38)92.5%92.7%78.1%78.2%42.6%43.4%
Open label (I2 11.9%)1.39 (1.22–1.58)1.39 (1.23–1.56)100%100%100%100%99.3%99.8%
Hospitalisation; overall (I2 49.2%)0.64 (0.31–1.29)0.72 (0.55–0.95)89.3%99.0%72.9%78.2%26.7%0.7%
Placebo-controlled (I2 54.4%)0.90 (0.22–3.71)0.90 (0.35–2.33)54.7%57.6%43.0%40.1%21.6%12.3%
Open label (I2 71.3%)0.44 (0.12–1.70)0.71 (0.59–0.94)89.1%99.8%81.3%85.3%57.6%0.3%

COVID-19: coronavirus disease 2019; HTN: hypertension; CAD: coronary artery disease; NNT: number needed to treat.